Skip to main content
TIBET AIM PHARM. INC. logo

TIBET AIM PHARM. INC. — Investor Relations & Filings

Ticker · 002826 ISIN · CNE100002C39 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,084 across all filing types
Latest filing 2025-04-24 Share Issue/Capital Cha…
Country CN China
Listing Shenzhen Stock Exchange 002826

About TIBET AIM PHARM. INC.

https://www.emyy.cn

Tibet Aim Pharm. Inc. is a pharmaceutical enterprise focused on the research, development, production, and distribution of medicinal products. The company integrates traditional Tibetan medicine with modern pharmaceutical manufacturing processes to develop a diverse portfolio of treatments. Its core product range typically includes cardiovascular medications, digestive system therapies, and specialized herbal formulations derived from high-altitude botanical sources. Tibet Aim Pharm. Inc. emphasizes the modernization of traditional formulas through rigorous clinical testing and standardized production techniques. The company serves healthcare providers and patients by providing therapeutic solutions that bridge ancient medical knowledge with contemporary scientific standards.

Recent filings

Filing Released Lang Actions
监事会关于公司2024年限制性股票激励计划预留授予激励对象名单（授予日）的核查意见
Share Issue/Capital Change Classification · 95% confidence The document is a supervisory board opinion on the 2024 restricted stock incentive plan reserved grant list for a company. It discusses compliance with laws and regulations regarding stock incentives and specifies the grant date and price for restricted stock awards. This is an announcement related to a stock incentive plan and the granting of shares to certain individuals. It does not contain financial statements or detailed financial results, nor is it a full report or presentation. It is an announcement about share-based incentives, which fits best under the category of Share Issue/Capital Change (SHA), as it relates to the issuance of restricted stock as part of an incentive plan.
2025-04-24 Chinese
2025年一季度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled "西藏易明西雅医药科技股份有限公司2025 年第一季度报告" which translates to "Tibet Yiming Xiya Pharmaceutical Technology Co., Ltd. 2025 First Quarter Report." It contains detailed financial data including balance sheets, profit and loss statements, cash flow statements, and explanations of financial changes for the first quarter of 2025. The document explicitly states it is a quarterly report and includes comprehensive financial statements and analysis for the quarter. It is not a brief announcement or a certification letter but a full financial report for a period shorter than a full fiscal year. Therefore, it fits the definition of an Interim / Quarterly Report (IR). Q1 2025
2025-04-24 Chinese
关于2024年度利润分配预案的公告
Notice of Dividend Amount Classification · 95% confidence The document is an announcement regarding the 2024 annual profit distribution plan of the company 西藏易明西雅医药科技股份有限公司. It details the proposed cash dividend per share, the basis for distribution, and the financial figures supporting the distribution plan. The document includes references to board and supervisory meetings where the plan was approved and mentions that the plan will be submitted to the 2024 annual shareholders' meeting for approval. The document is relatively short (2253 characters) and primarily serves as a formal announcement of the dividend distribution plan rather than a full financial report or annual report. It does not contain comprehensive financial statements or detailed financial analysis but focuses on dividend details and related approvals. Therefore, it fits best under the category of Notice of Dividend Amount (DIV), which covers announcements of dividend amounts, payment dates, and details for shareholders.
2025-04-24 Chinese
2025-025 关于向2024年限制性股票激励计划激励对象授予预留限制性股票的公告
Board/Management Information Classification · 95% confidence The document is a detailed announcement regarding the granting of reserved restricted shares under a 2024 restricted stock incentive plan by the company 西藏易明西雅医药科技股份有限公司. It includes specifics about the number of shares, grant price, recipients, approval procedures, performance conditions, and legal opinions. The content focuses on the company's board and supervisory committee decisions about stock incentives and related corporate governance matters. There is no financial statement or quarterly/annual report data, nor is it a transcript, earnings release, or dividend notice. The document is not a simple announcement of a report publication but a substantive disclosure about management and board decisions on stock incentives. This fits best under Board/Management Information (MANG), which covers announcements of changes or decisions involving senior management or board-level matters, including stock incentive plans for executives and key personnel.
2025-04-24 Chinese
关于使用自有资金进行现金管理的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from a company about the decision to use its own funds for cash management by investing in short-term, high-liquidity financial products. It details the investment amount, purpose, risk control measures, and approvals from the board and supervisory committee. The document does not contain financial statements or detailed financial data but rather informs shareholders and the public about the company's cash management plan and related approvals. It is a regulatory announcement about financing activities but not a full financial report or earnings release. Therefore, it fits best under Capital/Financing Update (CAP). The document length is 2454 characters, which is typical for an announcement rather than a full report.
2025-04-24 Chinese
2024年限制性股票激励计划预留部分限制性股票授予事项的法律意见书
Legal Proceedings Report Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the 2024 restricted stock incentive plan of a company. It details the legal review and approval process of the reserved portion of restricted stock grants, including compliance with relevant laws and regulations, board and shareholder approvals, and conditions for the stock grants. The document is not a financial report, earnings release, or management discussion, but a legal opinion related to a specific equity incentive plan. It does not announce voting results, changes in management, or capital structure changes, nor is it a regulatory filing or announcement of a report publication. The content fits best under a legal proceedings or legal opinion context related to corporate governance and compliance with securities laws. Given the specificity and nature of the document, the most appropriate classification is Legal Proceedings Report (LTR).
2025-04-24 Chinese

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.